AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33726834 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772 60 mg orally 2 or 3 times daily for 84 days
Number of subjects: 52
Study 33726834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 33726834 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772 60 mg
Number of subjects: 52
Study 32576791 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent endotracheal intubation (ETI)
Number of subjects: 543
Study 32576791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-intubation hypoxia (or an unobtainable pulse oximetry value) and younger than 1 year
Number of subjects: 543
Study 33986049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g carnosine for 15 weeks
Number of subjects: 50
Study 33986049 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 weeks
Number of subjects: 50
Study 32420695 — intervention group
Group type: EXPERIMENTAL
Intervention: ADSC‐CE topical solution applied twice daily
Number of subjects: 38
Study 32420695 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 38
Study 36449571 — intervention group
Group type: EXPERIMENTAL
Intervention: KETONE (0.29 g·kg‐1 of the ketone monoester (R)‐3‐hydroxybutyl (R)‐3‐hydroxybutyrate)
Number of subjects: 9
Study 36449571 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (no further nutrition provided)
Number of subjects: 9
Study 36449571 — intervention group
Group type: EXPERIMENTAL
Intervention: KETONE
Number of subjects: 9
Study 36449571 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 9
Study 33394936 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically derived spectacle corrections
Number of subjects: 30
Study 33394936 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective spectacle corrections derived from wavefront aberration data
Number of subjects: 30
Study 33394936 — intervention group
Group type: COMPARATOR
Intervention: Habitual corrections
Number of subjects: 30
Study 36194074 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app promoting Sharing, Mind, and Enjoyment (SME) behaviors, used daily over 1 month.
Number of subjects: 390
Study 36194074 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app promoting Sharing, Mind, and Enjoyment (SME) behaviors, used daily over 1 month (adherent subgroup).
Number of subjects: 390
Study 36194074 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app promoting Sharing, Mind, and Enjoyment (SME) behaviors.
Number of subjects: 390
Study 36194074 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no app usage during the study period).
Number of subjects: 390
Study 34261421 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill sprinting at steeper slopes
Number of subjects: 0
Study 34261421 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill sprinting at moderate slopes
Number of subjects: 0
Study 35285853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab (500 mg intravenous infusion)
Number of subjects: 1057
Study 35285853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1057
Study 35696054 — intervention group
Group type: EXPERIMENTAL
Intervention: RIV‐TDS Test Product (transdermal patch formulation of Rivastigmine with a release rate of 13.3 mg/24 h)
Number of subjects: 31
Study 35696054 — intervention group
Group type: COMPARATOR
Intervention: Exelon Marketed Reference Product (transdermal patch formulation of Rivastigmine with a release rate of 13.3 mg/24 h)
Number of subjects: 31
Study 35696054 — intervention group
Group type: EXPERIMENTAL
Intervention: RIV‐TDS Test Product
Number of subjects: 31
Study 35696054 — intervention group
Group type: COMPARATOR
Intervention: Exelon Marketed Reference Product
Number of subjects: 31
Study 32573779 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ADT (5 years)
Number of subjects: 303
Study 32573779 — intervention group
Group type: COMPARATOR
Intervention: Intermittent ADT
Number of subjects: 303
Study 33300394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion with higher CO2 concentration (CCWI)
Number of subjects: 15
Study 33300394 — intervention group
Group type: COMPARATOR
Intervention: Cold tap-water immersion (CWI)
Number of subjects: 15
Study 33300394 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 15
Study 33600354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiger II catheter
Number of subjects: 180
Study 33600354 — intervention group
Group type: COMPARATOR
Intervention: Judkins catheters (JR 4.0/JL 3.5)
Number of subjects: 180
Study 32926604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline (4, 6, or 8 mg/d)
Number of subjects: 315
Study 32926604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 32926604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline
Number of subjects: 315
Study 34878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care (SOC) systemic therapy plus radical prostatectomy (RP) and pelvic lymphadenectomy
Number of subjects: 50
Study 34878715 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) systemic therapy
Number of subjects: 50
Study 35485182 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Haizheng Pharmaceutical Group)
Number of subjects: 46
Study 35485182 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (AstraZeneca Pharmaceuticals LP)
Number of subjects: 46
Study 35485182 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 46
Study 33789567 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional shear wave elastography (2D-SWE)
Number of subjects: 215
Study 33789567 — intervention group
Group type: COMPARATOR
Intervention: Indocyanine green (ICG) clearance test (ICG-R15)
Number of subjects: 215
Study 33789567 — intervention group
Group type: COMPARATOR
Intervention: ALBI scores
Number of subjects: 215
Study 33789567 — intervention group
Group type: COMPARATOR
Intervention: APRI
Number of subjects: 215
Study 33789567 — intervention group
Group type: COMPARATOR
Intervention: FIB-4
Number of subjects: 215
Study 36271849 — intervention group
Group type: EXPERIMENTAL
Intervention: RCF 75 mg once daily (QD)
Number of subjects: 49
Study 36271849 — intervention group
Group type: EXPERIMENTAL
Intervention: RCF 225 mg QD
Number of subjects: 49
Study 36271849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 36271849 — intervention group
Group type: EXPERIMENTAL
Intervention: RCF (both doses)
Number of subjects: 49
Study 33435215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tualang honey
Number of subjects: 0
Study 33435215 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelam honey
Number of subjects: 0
Study 33435215 — intervention group
Group type: EXPERIMENTAL
Intervention: Kelulut honey
Number of subjects: 0
Study 35613823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic bracing (Spinova Osteo orthosis) in addition to standard care
Number of subjects: 98
Study 35613823 — intervention group
Group type: COMPARATOR
Intervention: Standard care (pain control with analgesics, physical therapy, and osteoporosis medication)
Number of subjects: 98
Study 32427541 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-provided graphic organizers (IP)
Number of subjects: 60
Study 32427541 — intervention group
Group type: COMPARATOR
Intervention: Student-generated graphic organizers (SG)
Number of subjects: 60
Study 35305845 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive immersive VR environment during burn wound care (Mean = 71.06, SD = 26.86)
Number of subjects: 48
Study 35305845 — intervention group
Group type: COMPARATOR
Intervention: Nature pictures viewed in VR goggles (Mean = 68.19, SD = 29.26)
Number of subjects: 48
Study 35305845 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer generated VR during wound care (Mean = 54.23, SD = 26.13)
Number of subjects: 48
Study 35305845 — intervention group
Group type: COMPARATOR
Intervention: No distraction (No VR) during wound care (Mean = 63.85, SD = 31.50)
Number of subjects: 48
Study 35305845 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive immersive VR
Number of subjects: 48
Study 35305845 — intervention group
Group type: COMPARATOR
Intervention: Nature pictures
Number of subjects: 48
Study 33467951 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 0
Study 33467951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (sucking ice cubes)
Number of subjects: 0
Study 33467951 — intervention group
Group type: EXPERIMENTAL
Intervention: OraLife, sea buckthorn pulp oil, marshmallow root tea, Helago chamomile oil, mare milk, Saliva Natura
Number of subjects: 0
Study 33467951 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwashes (teas, supplements, oil applications)
Number of subjects: 0
Study 35175284 — intervention group
Group type: COMPARATOR
Intervention: Black race compared with White race
Number of subjects: 9719
Study 35175284 — intervention group
Group type: COMPARATOR
Intervention: Medicare
Number of subjects: 9719
Study 35175284 — intervention group
Group type: COMPARATOR
Intervention: Medicaid
Number of subjects: 9719
Study 35175284 — intervention group
Group type: COMPARATOR
Intervention: Neighborhoods in the highest NDI quartile
Number of subjects: 9719
Study 33147353 — intervention group
Group type: EXPERIMENTAL
Intervention: CSLA
Number of subjects: 90
Study 33147353 — intervention group
Group type: COMPARATOR
Intervention: DNTP
Number of subjects: 90
Study 33147353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 33106892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide (SFOH)
Number of subjects: 85
Study 33106892 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate (CaAc)
Number of subjects: 85
Study 33240572 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure application at 25% of baseline IOP for 20 minutes
Number of subjects: 65
Study 33240572 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure application at 50% of baseline IOP for 20 minutes
Number of subjects: 65
Study 33240572 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure application at 75% of baseline IOP for 20 minutes
Number of subjects: 65
Study 33240572 — intervention group
Group type: COMPARATOR
Intervention: No negative pressure application (control)
Number of subjects: 65
Study 35689673 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 73866
Study 35689673 — intervention group
Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 73866
Study 33253391 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC-IT (1 × 10^6/kg)
Number of subjects: 48
Study 33253391 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC-IV (1 × 10^6/kg)
Number of subjects: 48
Study 33253391 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 48
Study 36164687 — intervention group
Group type: EXPERIMENTAL
Intervention: AUT00206
Number of subjects: 20
Study 36164687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33637332 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan (100 mg/d) with triple-antibiotic therapy (1500 mg/d metronidazole, 2000 mg/d tetracycline, and 1200 mg/d bismuth) for 7 days
Number of subjects: 21
Study 33637332 — intervention group
Group type: COMPARATOR
Intervention: Triple-antibiotic therapy (1500 mg/d metronidazole, 2000 mg/d tetracycline, and 1200 mg/d bismuth) with tegoprazan for 7 days
Number of subjects: 21
Study 32528467 — intervention group
Group type: EXPERIMENTAL
Intervention: Tick-borne encephalitis (TBE) vaccine
Number of subjects: 73
Study 36240389 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 375
Study 36240389 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAC videolaryngoscope
Number of subjects: 375
Study 36240389 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Trach videolaryngoscope
Number of subjects: 375
Study 36240389 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 375
Study 32590453 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmunoRatio
Number of subjects: 204
Study 32590453 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting by CP1
Number of subjects: 204
Study 32590453 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting by CP2
Number of subjects: 204
Study 32590453 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation (EB)
Number of subjects: 204
Study 32639369 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (informed it may be a local anaesthetic cream)
Number of subjects: 237
Study 32639369 — intervention group
Group type: COMPARATOR
Intervention: Control group (informed the cream was inactive)
Number of subjects: 237
Study 33004536 — intervention group
Group type: EXPERIMENTAL
Intervention: Abituzumab 1500 mg
Number of subjects: 24
Study 33004536 — intervention group
Group type: EXPERIMENTAL
Intervention: Abituzumab 500 mg
Number of subjects: 24
Study 33004536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32340820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (4 mg/kg IM or 1 mg/kg IV)
Number of subjects: 93
Study 32340820 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5-10 mg IM or IV) + Lorazepam (1-2 mg IM or IV)
Number of subjects: 93
Study 32034312 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic pedicled phalloplasty (SPP)
Number of subjects: 34
Study 35742327 — intervention group
Group type: EXPERIMENTAL
Intervention: Active air filtration intervention
Number of subjects: 38
Study 35742327 — intervention group
Group type: COMPARATOR
Intervention: Sham air filtration intervention
Number of subjects: 38
Study 33689608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens dislocation cases
Number of subjects: 508
Study 33689608 — intervention group
Group type: COMPARATOR
Intervention: Controls (without intraocular lens dislocation)
Number of subjects: 508
Study 32573670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg)
Number of subjects: 394
Study 32573670 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride)
Number of subjects: 394
Study 34801998 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min aerobic exercise on a cycle ergometer
Number of subjects: 8
Study 34801998 — intervention group
Group type: COMPARATOR
Intervention: Resting moment (30-min sitting in a chair)
Number of subjects: 8
Study 34009015 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyphosate (GLY)
Number of subjects: 247
Study 34009015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminomethylphosphonic Acid (AMPA)
Number of subjects: 247
Study 34009015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 247
Study 36347106 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided group (standard PE + virtual, clinician-guided IVEs with Bio Ware)
Number of subjects: 40
Study 36347106 — intervention group
Group type: COMPARATOR
Intervention: Non-Guided group (standard PE + self-guided IVEs with Bio Ware)
Number of subjects: 40
Study 33715077 — intervention group
Group type: EXPERIMENTAL
Intervention: TEGAFOX (tegafur–uracil/leucovorin plus oxaliplatin)
Number of subjects: 159
Study 33715077 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV (tegafur–uracil/leucovorin)
Number of subjects: 159
Study 33715077 — intervention group
Group type: EXPERIMENTAL
Intervention: TEGAFOX
Number of subjects: 159
Study 33715077 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV
Number of subjects: 159
Study 33715077 — intervention group
Group type: EXPERIMENTAL
Intervention: TEGAFOX and UFT/LV
Number of subjects: 159
Study 32840597 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/d)
Number of subjects: 192
Study 32840597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 35239175 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemodiafiltration
Number of subjects: 193
Study 35239175 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemodiafiltration (subgroup with convective volume > 27.5 L)
Number of subjects: 193
Study 32858227 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Emergency Department Innovations (GEDI) program
Number of subjects: 840
Study 32858227 — intervention group
Group type: COMPARATOR
Intervention: Usual ED care
Number of subjects: 840
Study 35623576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 81
Study 35623576 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 81
Study 35623576 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat challenges
Number of subjects: 81
Study 35623576 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom pattern reproducibility
Number of subjects: 81
Study 35749350 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 204
Study 35749350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 204
Study 35749350 — intervention group
Group type: COMPARATOR
Intervention: Baseline model
Number of subjects: 204
Study 35749350 — intervention group
Group type: COMPARATOR
Intervention: Radiologists' performance
Number of subjects: 204
Study 34870120 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain neurophysiology education in addition to routine education (n=21)
Number of subjects: 41
Study 34870120 — intervention group
Group type: COMPARATOR
Intervention: Routine education only (control group, n=20)
Number of subjects: 41
Study 33612485 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine plus vasopressin (0.1 mL per kg vasopressin, 0.1 mL per kg epinephrine 1:10000)
Number of subjects: 90
Study 33612485 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine plus placebo (0.1 mL per kg normal saline, 0.1 mL per kg epinephrine 1:10000)
Number of subjects: 90
Study 33612485 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine plus vasopressin
Number of subjects: 90
Study 33612485 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine plus placebo
Number of subjects: 90
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from others than family/friends
Number of subjects: 4681
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from family
Number of subjects: 4681
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from friends
Number of subjects: 4681
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic performance
Number of subjects: 4681
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Activeness of participation in school activities
Number of subjects: 4681
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonious relationship with teachers/classmates
Number of subjects: 4681
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Health over the last year
Number of subjects: 4681
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical exercise
Number of subjects: 4681
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 4681
Study 32324755 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme worry about their own lives
Number of subjects: 4681
Study 35837022 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 40, 50, 60, 70, and 80 μg for severe preeclampsia
Number of subjects: 150
Study 35837022 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 70, 80, 90, 100, and 110 μg for normotension
Number of subjects: 150
Study 34214822 — intervention group
Group type: EXPERIMENTAL
Intervention: My Memory Forest intervention
Number of subjects: 56
Study 34214822 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 56
Study 34964395 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance program (45 minute sessions two days per week over eight weeks)
Number of subjects: 41
Study 34964395 — intervention group
Group type: COMPARATOR
Intervention: No-PE control group
Number of subjects: 41
Study 33935121 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based nursing intervention
Number of subjects: 116
Study 35346389 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape, elevation and massage (Trial Treatment - TT)
Number of subjects: 26
Study 35346389 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (compression, elevation and massage - TAU)
Number of subjects: 26
Study 34551130 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 431
Study 34551130 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg
Number of subjects: 431
Study 34551130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 34551130 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab (both doses)
Number of subjects: 431
Study 34551130 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab
Number of subjects: 431
Study 35093129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intertruncal approach to the supraclavicular block (IA-SB)
Number of subjects: 122
Study 35093129 — intervention group
Group type: COMPARATOR
Intervention: Classical approach to the supraclavicular block (CA-SB)
Number of subjects: 122
Study 33045536 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser tongue debridement (LTD) with an Er,Cr:YSGG solid state laser
Number of subjects: 54
Study 33303222 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (3 g/day)
Number of subjects: 21
Study 33303222 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (3 g/day)
Number of subjects: 21
Study 35245642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit U intervention
Number of subjects: 267
Study 35245642 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring only group
Number of subjects: 267
Study 33094919 — intervention group
Group type: EXPERIMENTAL
Intervention: Before breakfast (BB)
Number of subjects: 140
Study 34187833 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-collection of anal canal specimen at 0 and 12 months
Number of subjects: 400
Study 34187833 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based clinician collection of anal canal specimen at 0 and 12 months
Number of subjects: 400